STAT July 25, 2024
Andrew Joseph

LONDON — In the booming field of weight loss drugs, Roche has been riding high in recent months, with back-to-back positive studies of two experimental medicines that sent the company’s shares up — and those of its rivals down.

But on Thursday, company executives faced an onslaught of questions from analysts during an earnings presentation about what could come next for the company’s weight loss drugs and how they...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
First Comprehensive Review of SMA Drugs Offers Long-Term Insights, Outcome Gaps
Health Rounds: Next Generation Lilly Weight-loss Drug Shows Added Heart, Liver Benefits
Drugmaker might be 1st healthcare company to top $1 trillion valuation
Pharma Pulse 9/5/24: Legal Advice for DSCSA Compliance Teams, Pharmacy Students Discuss Learning Through Social Media Platforms & more
RNA treatment shows promise for enhancing memory and reducing anxiety

Share This Article